Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PMD-028
- Development stage
- Preclinical
- Lead developer
- Phoenix Molecular Designs
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PMD-028 is a preclinical small molecule drug candidate being developed by Phoenix Molecular Designs (PMD Group). It is currently being investigated for the treatment of hematological malignancies and inflammatory conditions, specifically myelofibrosis and acute myeloid leukemia (AML). While the company's lead candidate, PMD-026, is a known RSK2 inhibitor, the specific molecular target for PMD-028 has not been publicly disclosed in the provided pipeline information, though it is positioned within the same therapeutic areas of oncology and inflammation. Phoenix Molecular Designs generally focuses on the development of Ribosomal S6 Kinase (RSK) inhibitors.
Beyond the preview
Go deeper on PMD-028.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PMD-028.